PRNewsWire
21 Aug 2026, 08:33 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Capricor Therapeutics (CAPR) is facing a class action lawsuit alleging it made false and misleading statements regarding clinical data for the drug Deramiocel. — Securities litigation alleging fraud regarding a core product candidate typically triggers investor uncertainty and downward price pressure.
-0.60The lawsuit claims Capricor modified its statistical analysis plan for Deramiocel without securing the FDA's agreement before resubmitting its Biologics License Application. — Lack of FDA alignment on analysis plans significantly increases the risk of regulatory rejection or delays for the drug's approval.
-0.50Which stocks this story touches
The company is mentioned as being sued for securities law violations.
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is mentioned as being sued for securities law violations.
The company is facing a class action lawsuit alleging false and misleading statements regarding clinical data and FDA filings.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
1h ago
